PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21532269-6	2011	The mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 and the p38 inhibitor SB203580 were used to examine the signaling pathway associated with the mRNA expression of tyrosinase, TRP-1, or TRP-2 when B16 melanoma cells were treated with minocycline.	SB 203580	95-103	tyrosinase	Mus musculus	186-196	
21667118-8	2011	The inhibition of p38 MAPK pathway by SB203580 led to the suppression of tyrosinase, TRP-1, and TRP-2 expression in cells treated with ascorbic acid.	SB 203580	38-46	tyrosinase	Mus musculus	73-83	
29621941-6	2018	However, resorcinol-induced decrease in melanin content, tyrosinase activity, and tyrosinase protein levels were attenuated by SB203580, a p38 MAPK inhibitor.	SB 203580	127-135	tyrosinase	Mus musculus	57-92	
29019920-11	2017	The findings from an assay searching for the inhibitor revealed that SB203580 (a specific p38 inhibitor) or SP600125 (a p-JNK inhibitor) attenuated pratol-induced cellular tyrosinase activity whereas PD98059 (an ERK inhibitor) did not.	SB 203580	69-77	tyrosinase	Mus musculus	172-182	
21532269-7	2011	The SB203580 inhibited the mRNA expression of tyrosinase and TRP-1, suggesting the minocycline-induced melanogensis occurred via a p38 signaling pathway.	SB 203580	4-12	tyrosinase	Mus musculus	46-56	
17521910-6	2007	SB203580, a selective inhibitor of p38 MAPK, completely blocked cubebin-induced expression of tyrosinase mRNA in B16 cells.	SB 203580	0-8	tyrosinase	Mus musculus	94-104	
15760340-6	2005	SB203580, a p38 MAPK inhibitor, completely blocked the PTLF-induced melanogenesis by inhibiting promoter activity and subsequent expression of tyrosinase.	SB 203580	0-8	tyrosinase	Mus musculus	143-153